S&P 500: 669.03 +1.0% NASDAQ 100: 600.38 +1.1% Dow Jones: 470.30 +0.8%

Krystal Biotech, Inc.

KRYS Healthcare
$250.16 +$2.9 (1.17%)
Market Cap: $7.31 B
Gurus Holding
6
Popularity Rank
#1453
% of Shares Held
0.12%
Net Activity (Q4 2025)
+$683,653.97

Guru Ownership Trend

Guru Analysis for Krystal Biotech, Inc. (KRYS)

Krystal Biotech, Inc. (KRYS), a key player in the Healthcare sector, continues to attract institutional attention.

As of Q4 2025, a total of 6 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $8.49 M.

Top institutional holders include Cliff Asness and Ray Dalio.

Institutional sentiment is currently Bullish. This is evidenced by a $683,653.97 net inflow during the quarter.

Recent activity highlights Ken Fisher who opened a new position. Conversely, Cliff Asness reduced exposure by 29.7%.

Key Holders

Top 5 by Value

$3.49 M
$2.47 M
$933,399
$338,993

Top 5 by Conviction

Recent Activity Breakdown (Q4 2025)

+$2.16 M
Total Buy Value
New Buys 3
Additions 1
-$1.47 M
Total Sell Value
Reductions 2
Sold Out 0

Guru Consensus (Q4 2025)

Based on recent activity
Net Sellers
2
Net Buyers
4

FAQs for Krystal Biotech, Inc. (KRYS)

Major holders include Cliff Asness ($3.49 M), Ray Dalio ($2.47 M), Ken Fisher ($933,399). According to the latest reported data, 6 tracked investment managers collectively hold approximately 33,936 shares.

According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $683,653.97, with 4 managers increasing positions and 2 managers reducing holdings.

During the most recent reporting period, 2 managers trimmed their positions, while 0 fully exited KRYS. The total reported sell value was $1.47 M.

Yes, 3 managers opened new positions in KRYS, and 1 increased their existing holdings. The total reported buy value was $2.16 M.

Portfolio Manager % Portfolio Activity Shares Value Report Date
0.00% Reduce -29.7% 14,157 $3.49 M Q4 2025
0.01% Add 3.0% 10,015 $2.47 M Q4 2025
0.00% New Buy 3,786 $933,399 Q4 2025
0.00% New Buy 3,300 $813,582 Q4 2025
0.00% New Buy 1,375 $338,993 Q4 2025
0.00% Reduce -0.3% 1,303 $321,242 Q4 2025
Date
Insider Name
Transaction
Value
Shares
Position / Chg
SEC Form